Quoin Pharmaceuticals (QNRX) Total Non-Current Liabilities (2017 - 2026)

Quoin Pharmaceuticals has reported Total Non-Current Liabilities for 10 years, with the latest figure at $4.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 2.26% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 2.26% YoY) and the FY2025 annual result came in at $4.9 million, up 38.15% from the prior year.
• Total Non-Current Liabilities eased to $4.7 million in Q1 2026 per QNRX's latest filing, from $4.9 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $5.8 million in Q3 2025 and troughed at -$2.6 million in Q3 2022.
• A 5-year average of $3.7 million and a median of $3.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The widest YoY moves for Total Non-Current Liabilities: up 340.43% in 2022, down 64.84% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $2.9 million in 2022, then advanced by 22.34% to $3.6 million in 2023, then decreased by 0.02% to $3.6 million in 2024, then surged by 38.15% to $4.9 million in 2025, then declined by 4.06% to $4.7 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $4.7 million, $4.9 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.